美国食品药品监督管理局关于麻醉与脑发育的警告:对产科与胎儿手术的影响
文章解读美国食品药品监督管理局(FDA)2016年12月14日关于孕期第三季度暴露于某些麻醉药可能损害儿童脑发育的警告,分析其对产科和胎儿手术麻醉管理的影响,并列出可能规避胎儿长期神经学不良影响的策略。
要点
- FDA警告:妊娠第三季度暴露于异氟烷、七氟烷、地氟烷、丙泊酚和咪达唑仑可能与儿童脑发育受损相关。
- 健康专业人员应权衡幼儿和孕妇适当麻醉的获益与潜在风险,尤其是手术可能超过3小时或3岁以下儿童需多次手术时。
- 可考虑使用非γ-氨基丁酸激动剂如阿片类或右美托咪定镇静、缩短吸入麻醉暴露时间、加快手术开始以缩短麻醉诱导至手术开始的间隔。
核心结论
- FDA警告提示妊娠第三季度暴露于特定麻醉药可能与儿童脑发育受损相关,产科与胎儿手术麻醉管理需权衡获益与风险。
研究设计与样本
- 本文为针对FDA警告的解读性文章,未报告系统检索范围或样本量。
主要发现
- 小动物模型和非人灵长类临床前研究提示新生儿和晚孕期胎儿麻醉暴露后可能出现脑细胞丢失或死亡及神经认知功能受损。
- 该领域人体研究有限且目前尚无定论。
- 剖宫产中全身麻醉胎儿暴露时间短,未与学习障碍相关联。
- 非产科或胎儿手术中胎儿可暴露于静脉和吸入麻醉药,暴露时间通常长于剖宫产。
- 很少研究探讨孕中期麻醉暴露对胎儿的影响,而多数非产科和胎儿手术在孕中期进行。
关键数值与推荐
- FDA警告涉及异氟烷、七氟烷、地氟烷、丙泊酚和咪达唑仑。
- 警告建议健康专业人员权衡幼儿和孕妇适当麻醉的获益与潜在风险,尤其是手术可能超过3小时或3岁以下儿童需多次手术时。
- 可能规避胎儿长期神经学不良影响的策略包括:适当使用非γ-氨基丁酸激动剂如阿片类(瑞芬太尼、芬太尼)或α-2激动剂右美托咪定镇静。
- 在安全范围内尽可能缩短胎儿、产科和非产科手术中吸入麻醉药的暴露时间。
- 及时开始手术并限制麻醉诱导至手术开始的间隔以帮助减少患者吸入麻醉药暴露。
临床怎么用
- 作者建议临床医生在为患者安排非产科和胎儿手术时应考虑将实施的麻醉类型和潜在风险。
局限性
- 该领域人体研究有限且目前尚无定论。
- 很少研究探讨孕中期麻醉暴露对胎儿的影响,而多数非产科和胎儿手术在孕中期进行。
- 胎儿脑在此发育阶段的可塑性如何调节麻醉暴露的后果尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There has been growing concern about the detrimental effects of certain anesthetic agents on the developing brain. Preclinical studies in small animal models as well as nonhuman primates suggested loss or death of brain cells and consequent impaired neurocognitive function following anesthetic exposure in neonates and late gestation fetuses. Human studies in this area are limited and currently inconclusive. On Dec. 14, 2016, the US Food and Drug Administration issued a warning regarding impaired brain development in children following exposure to certain anesthetic agents used for general anesthesia, namely the inhalational anesthetics isoflurane, sevoflurane, and desflurane, and the intravenous agents propofol and midazolam, in the third trimester of pregnancy. Furthermore, this warning recommends that health care professionals should balance the benefits of appropriate anesthesia in young children and pregnant women against potential risks, especially for procedures that may last >3 hours or if multiple procedures are required in children <3 years old. The objective of this article is to highlight how the Food and Drug Administration warning may impact the anesthetic and surgical management of the obstetric patient. Neuraxial anesthesia (epidural or spinal anesthesia) is more commonly administered for cesarean delivery than general anesthesia. The short duration of fetal exposure to general anesthesia during cesarean delivery has not been associated with learning disabilities. However, the fetus can also be exposed to both intravenous and inhalation anesthetics during nonobstetric or fetal surgery in the second and third trimester; this exposure is typically longer than that for cesarean delivery. Very few studies address the effect of anesthetic exposure on the fetus in the second trimester when most nonobstetric and fetal surgical procedures are performed. It is also unclear how the plasticity of the fetal brain at this stage of development will modulate the consequences of anesthetic exposure. Strategies that may circumvent possible untoward long-term neurologic effects of anesthesia in the baby include: (1) use of nonimplicated (nongamma-aminobutyric acid agonist) agents for sedation such as opioids (remifentanil, fentanyl) or the alpha-2 agonist, dexmedetomidine, when appropriate; (2) minimizing the duration of exposure to inhalational anesthetics for fetal, obstetric, and nonobstetric procedures in the pregnant patient, as much as possible within safe limits; and (3) commencing surgery promptly and limiting the interval between induction of anesthesia and surgery start time will help decrease patient exposure to inhalational agents. While the Food and Drug Administration warning was based on duration and repetitive nature of exposure rather than concentration of inhalational agents, intravenous tocolytics can be considered for intraoperative use, to provide uterine relaxation for fetal surgery, in lieu of high concentrations of inhalational anesthetic agents. Practitioners should consider the type of anesthesia that will be administered and the potential risks when scheduling patients for nonobstetric and fetal surgery.
引用
- Olutoye OA, Baker BW, Belfort MA, et al. Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery. Am J Obstet Gynecol. 2017. PMID: 28888583. doi:10.1016/j.ajog.2017.08.107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。